Effect of Ripasudil on Visual Outcomes in Pseudophakic Corneal Edema: A Prospective Interventional Study

Purpose: To evaluate the efficacy of Ripasudil, a Rho-kinase inhibitor, in managing pseudophakic corneal edema following cataract surgery and comparison with the conventional treatment. Methods:In this prospective interventional study, 104 patients with pseudophakic corneal edema were divided into two groups end were administered either 0.4% Ripasudil ophthalmic solution (Group A) or 5% hypertonic saline (Group B).Visual acuity, central corneal thickness (CCT), and intraocular pressure (IOP) were evaluated along with time taken for resolution of corneal edema over a period of six months.Results: Significant improvements in BCVA, corneal clarity and CCT were observed in both groups, with slightly earlier improvements in Group A which was not statistically significant.No serious adverse effects were reported.Conclusion: Ripasudil 0.4% ophthalmic solution is not inferior to 5% hypertonic saline drops in improving visual outcomes and reducing corneal edema in patients with pseudophakic corneal edema following cataract surgery and that it is safe, effective, and potentially offers endothelial benefits.It may serve as a non-invasive therapeutic alternative in pseudophakic corneal edema.